Breast cancer biomarkers: risk assessment, diagnosis, prognosis, prediction of treatment efficacy and toxicity, and recurrence

AM Braden, RV Stankowski, JM Engel… - Current …, 2014 - ingentaconnect.com
Breast cancer is the most common cancer amongst women in the United States and around
the world. Although widespread use of adjuvant chemotherapeutic and hormonal agents …

[HTML][HTML] Chemotherapy and cardiotoxicity

H Broder, RA Gottlieb, NE Lepor - Reviews in cardiovascular …, 2008 - ncbi.nlm.nih.gov
Newer cancer therapies have improved the survival of patients with cancer and, in some
cases, turned cancer into a chronic disease. Patients are now surviving long enough for the …

[HTML][HTML] Injectable hydrogels for the sustained delivery of a HER2-targeted antibody for preventing local relapse of HER2+ breast cancer after breast-conserving …

X Chen, M Wang, X Yang, Y Wang, L Yu, J Sun… - Theranostics, 2019 - ncbi.nlm.nih.gov
A high risk of local relapse is the main challenge of HER2+ breast cancer after breast-
conserving surgery. We aimed to develop a long-acting delivery system for Herceptin, a …

High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study

AA Onitilo, JM Engel, RV Stankowski, H Liang… - Breast cancer research …, 2012 - Springer
Monitoring of left ventricular ejection fraction (LVEF) is the current standard for detection of
trastuzumab-induced cardiotoxicity; however, time-to-diagnosis and cost of assessment are …

[HTML][HTML] Computer-assisted determination of left ventricular endocardial borders reduces variability in the echocardiographic assessment of ejection fraction

E Maret, L Brudin, L Lindstrom, E Nylander… - Cardiovascular …, 2008 - Springer
Background Left ventricular size and function are important prognostic factors in heart
disease. Their measurement is the most frequent reason for sending patients to the echo …

[HTML][HTML] Hydrogel-bound cytotoxic drug delivery system for breast cancer

PK Goyal, S Khurana, A Mittal - Health Sciences Review, 2023 - Elsevier
Breast cancer was first noted by the ancient Egyptians more than 3500 years ago. In India,
the US, and China about 221757, 287750, and 429105 cases of breast cancer were …

Erythropoietin pretreatment protects against acute chemotherapy toxicity in isolated rat hearts

A Ramond, E Sartorius, M Mousseau… - Experimental …, 2008 - journals.sagepub.com
The use of chemotherapeutic agents, such as anthracycline or trastuzumab, in oncology is
limited by their cardiac toxicity. Recent experimental studies suggest that recombinant …

Observational study of trastuzumab-related cardiotoxicity in early and metastatic breast cancer

LR Grazziotin, PD Picon - Journal of Oncology Pharmacy …, 2017 - journals.sagepub.com
Introduction Trastuzumab-related cardiotoxicity has been a major concern in clinical
practice, since observational studies have shown higher incidences than that reported in …

Simultaneous hemodynamic and serological cardiotoxicity monitoring during immunotherapy with trastuzumab

K Knobloch, J Tepe, R Lichtinghagen, HJ Luck… - International journal of …, 2008 - Elsevier
BACKGROUND: Immunotherapy with trastuzumab (Herceptin), a selective HER-2 (ErbB2)-
antibody, is associated with a certain degree of cardiotoxicity. This study sought to evaluate …

[HTML][HTML] Не-антрациклиновая кардиотоксичность

МГ Матяш, ТЛ Кравчук, ВВ Высоцкая… - Сибирский …, 2009 - cyberleninka.ru
Представлены современные данные о кардиотоксичности цитостатиков, за
исключением антрациклиновых антибиотиков и препаратов таргетной терапии …